Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Smarttech247 Group plc specializes in cybersecurity software solutions, primarily targeting the UK and European markets. The company differentiates itself through its proprietary AI-driven threat detection technology, which enhances its competitive position in a rapidly evolving cybersecurity landscape.
Smarttech247 generates revenue primarily through subscription-based software licenses, which provide recurring income and enhance customer retention. The company's competitive advantage lies in its advanced AI algorithms that offer superior threat detection and response capabilities, allowing it to command premium pricing.
Changes in cybersecurity regulations impacting demand for compliance solutions
Adoption rates of AI technologies in threat detection
Competitive landscape shifts, particularly from larger players entering the market
Customer retention rates and expansion within existing accounts
Rapid technological changes in cybersecurity could render existing solutions obsolete
Increased regulatory scrutiny may impose additional compliance costs
Emergence of new competitors with disruptive technologies
Potential price competition from larger, established firms
Limited cash flow generation could impact R&D investment
Low net margins (1.0%) may restrict financial flexibility
moderate - as a technology provider, Smarttech247's performance is linked to overall IT spending, which correlates with GDP growth.
Low - the company's low debt levels (Debt/Equity of 0.02) mean financing costs are minimal, but higher rates could impact overall IT budgets.
minimal - the company is not heavily reliant on credit for operations.
growth - investors are likely attracted to the company's potential for rapid expansion in the cybersecurity market.
high - the stock has exhibited significant price fluctuations, as evidenced by a 63.3% decline over the past year.